MA49913A - RNA POLYMERASE VARIANTS - Google Patents

RNA POLYMERASE VARIANTS

Info

Publication number
MA49913A
MA49913A MA049913A MA49913A MA49913A MA 49913 A MA49913 A MA 49913A MA 049913 A MA049913 A MA 049913A MA 49913 A MA49913 A MA 49913A MA 49913 A MA49913 A MA 49913A
Authority
MA
Morocco
Prior art keywords
rna polymerase
polymerase variants
variants
rna
polymerase
Prior art date
Application number
MA049913A
Other languages
French (fr)
Inventor
Athanasios Dousis
Elissa Hobert
Amy E Rabideau
Kanchana Ravichandran
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA49913A publication Critical patent/MA49913A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11023—[RNA-polymerase-subunit] kinase (2.7.11.23)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA049913A 2017-08-18 2018-08-17 RNA POLYMERASE VARIANTS MA49913A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762547677P 2017-08-18 2017-08-18
US201862628484P 2018-02-09 2018-02-09
US201862638684P 2018-03-05 2018-03-05
US201862677527P 2018-05-29 2018-05-29

Publications (1)

Publication Number Publication Date
MA49913A true MA49913A (en) 2021-05-05

Family

ID=65362870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049913A MA49913A (en) 2017-08-18 2018-08-17 RNA POLYMERASE VARIANTS

Country Status (6)

Country Link
US (4) US10526629B2 (en)
EP (2) EP3668971B8 (en)
JP (2) JP7408098B2 (en)
CN (1) CN111212905A (en)
MA (1) MA49913A (en)
WO (1) WO2019036682A1 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2746406C2 (en) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Vaccines based on nucleic acids
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. Human cytomegalovirus vaccine
PE20181529A1 (en) 2015-10-22 2018-09-26 Modernatx Inc NUCLEIC ACID VACCINES FOR VARICELA-ZOSTER VIRUS (VZV)
PT3718565T (en) 2015-10-22 2022-07-20 Modernatx Inc Respiratory virus vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
DK3386484T3 (en) 2015-12-10 2022-07-04 Modernatx Inc COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. Analytical hplc methods
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US11072808B2 (en) * 2018-10-04 2021-07-27 New England Biolabs, Inc. Methods and compositions for increasing capping efficiency of transcribed RNA
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
EP3927821A4 (en) 2019-02-20 2023-01-25 ModernaTX, Inc. Rna polymerase variants for co-transcriptional capping
EP3938507A4 (en) * 2019-03-11 2023-02-22 ModernaTX, Inc. Fed-batch in vitro transcription process
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
US20230108894A1 (en) 2020-01-28 2023-04-06 Moderna TX, Inc Coronavirus rna vaccines
AU2021215938A1 (en) 2020-02-07 2022-09-01 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
MX2022013254A (en) 2020-04-22 2023-01-24 BioNTech SE Coronavirus vaccine.
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022067010A1 (en) 2020-09-25 2022-03-31 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
WO2022081764A1 (en) 2020-10-14 2022-04-21 RNAimmune, Inc. PAN-RAS mRNA CANCER VACCINES
CA3198726A1 (en) * 2020-10-15 2022-04-21 Translate Bio, Inc. Large scale synthesis of messenger rna
JP2023549592A (en) * 2020-10-20 2023-11-28 エスティー ファーム カンパニー リミテッド 5'-capped oligonucleotide for RNA synthesis
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
CN112831484B (en) * 2021-01-13 2022-09-20 华中科技大学 T7-RNA polymerase mutant and application thereof
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
EP4277653A1 (en) 2021-01-15 2023-11-22 ModernaTX, Inc. Variant strain-based coronavirus vaccines
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2022237382A1 (en) 2021-03-15 2023-09-28 Modernatx, Inc. Therapeutic use of sars-cov-2 mrna domain vaccines
US20240229109A1 (en) 2021-04-01 2024-07-11 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
AU2022258335A1 (en) 2021-04-13 2023-11-23 Modernatx, Inc. Respiratory virus combination vaccines
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
WO2022266389A1 (en) 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
TW202321446A (en) 2021-08-13 2023-06-01 美商現代公司 Multicolumn chromatography mrna purification
EP4396337A1 (en) * 2021-09-01 2024-07-10 GlaxoSmithKline Biologicals S.A. T7 rna polymerase variants for rna synthesis
KR20240090727A (en) 2021-10-22 2024-06-21 세일 바이오메디슨스, 인크. mRNA vaccine composition
EP4426853A1 (en) 2021-11-01 2024-09-11 ModernaTX, Inc. Mass spectrometry of mrna
EP4426855A1 (en) 2021-11-05 2024-09-11 ModernaTX, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
AU2023213852A1 (en) * 2022-01-27 2024-08-15 Trilink Biotechnologies, Llc Trinucleotide cap analogs and methods of use thereof
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023201204A1 (en) 2022-04-11 2023-10-19 Modernatx, Inc. Detection of mrna purity in a mixture
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
CN114703162B (en) * 2022-04-24 2023-08-08 江南大学 T7RNA polymerase mutant with high transcription activity and application thereof
WO2023225524A1 (en) 2022-05-17 2023-11-23 Modernatx, Inc. Preparation of highly concentrated mrna
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2023235362A1 (en) * 2022-05-31 2023-12-07 Nutcracker Therapeutics, Inc. Rna cap analogs and methods of use
WO2023250119A1 (en) 2022-06-24 2023-12-28 Modernatx, Inc. Methods of producing rna
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
CN115975974B (en) * 2022-07-06 2024-08-06 华中科技大学 T7-RNA polymerase mutant suitable for in vitro synthesis of RNA and application thereof
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024026287A2 (en) * 2022-07-25 2024-02-01 University Of Utah Research Foundation Synthesis of substoichiometric chemically modified mrnas by in vitro transcription
WO2024026005A1 (en) 2022-07-28 2024-02-01 Modernatx, Inc. Methods of rna purification
WO2024044741A2 (en) * 2022-08-26 2024-02-29 Trilink Biotechnologies, Llc Efficient method for making highly purified 5'-capped oligonucleotides
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024153793A1 (en) 2023-01-20 2024-07-25 Astrazeneca Ab Nucleic acid molecules
WO2024153794A1 (en) 2023-01-20 2024-07-25 Astrazeneca Ab Vaccine
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
WO2024163465A1 (en) 2023-01-30 2024-08-08 Modernatx, Inc. Epstein-barr virus mrna vaccines
EP4414460A1 (en) * 2023-02-07 2024-08-14 Arcticzymes AS Compositions comprising a sequence specific endoribonuclease and methods of use
WO2024185734A1 (en) * 2023-03-03 2024-09-12 株式会社ナティアス Polyphosphorylated nucleoside, phosphate-activated nucleotide used for synthesis of polyphosphorylated nucleoside and method for synthesis of same, and method for synthesis of polyphosphorylated nucleoside using phosphate-activated nucleotide
CN116926098B (en) * 2023-07-31 2024-07-23 态创生物科技(广州)有限公司 Directed evolution system and method for enhancing T7 RNAP transcriptional activity on collagen/elastin
GB202406294D0 (en) 2024-05-06 2024-06-19 Thermo Fisher Scientific Baltics Uab Methods and compositions for producing capped mRNA

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2279675A1 (en) 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for localizing a nucleic acid construct within a cell for therapeutic and diagnostic uses
FR2822164B1 (en) 2001-03-19 2004-06-18 Centre Nat Rech Scient POLYPEPTIDES DERIVED FROM POLYMERASE RNAS, AND USES THEREOF
EP4332227A1 (en) 2005-08-23 2024-03-06 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US9012219B2 (en) * 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
EP2010659B1 (en) 2006-04-14 2014-06-18 CellScript, Inc. Kits and methods for generating 5' capped RNA
WO2009021191A2 (en) 2007-08-08 2009-02-12 Barnes Wayne M Improved t7 expression system
CN102177236B (en) * 2008-08-08 2013-11-06 东曹株式会社 RNA polymerase mutant with improved functions
RU2016112465A (en) 2009-08-21 2018-11-27 Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. RECOMBINANT VACCINE BASED ON PARAMYXOVIRUSES OF BIRDS AND METHOD FOR PREPARING AND USING IT
JP2011223982A (en) * 2010-03-30 2011-11-10 Tosoh Corp T7rna polymerase-fused protein
US9193959B2 (en) 2010-04-16 2015-11-24 Roche Diagnostics Operations, Inc. T7 RNA polymerase variants with enhanced thermostability
EP2377938A1 (en) 2010-04-16 2011-10-19 Eukarys Capping-prone RNA polymerase enzymes and their applications
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012045082A2 (en) 2010-10-01 2012-04-05 Jason Schrum Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
ES2538694T3 (en) * 2011-04-01 2015-06-23 F. Hoffmann-La Roche Ag Variants of the T7 RNA polymerase with Cysteine-Serine substitutions
EP2694670B1 (en) 2011-04-08 2017-07-19 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
BR112013029490A2 (en) 2011-05-17 2019-09-24 Moderna Therapeutics Inc engineered nucleic acids and methods of use for non-human vertebrates
EP3587573A1 (en) 2011-06-16 2020-01-01 The Regents of The University of California Synthetic gene clusters
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2755693A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc Engineered nucleic acids and methods of use thereof
FR2981088B1 (en) 2011-10-06 2013-11-29 Biomerieux Sa RNA POLYMERASES MUTEES
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
DK2791160T3 (en) 2011-12-16 2022-05-30 Modernatx Inc MODIFIED MRNA COMPOSITIONS
WO2013096709A2 (en) 2011-12-21 2013-06-27 modeRNA Therapeutics Methods of increasing the viability or longevity of an organ or organ explant
DK2798064T3 (en) * 2011-12-30 2016-12-19 Cellscript Llc PRODUCTION AND USE OF IN VITRO synthesized ssRNA TO FEED IN MAMMALIAN CELLS FOR INDUCTION OF A BIOLOGICAL OR BIOCHEMICAL EFFECT
US9045740B2 (en) 2012-02-24 2015-06-02 University Of Massachusetts Modified T7-related RNA polymerases and methods of use thereof
WO2013148867A1 (en) 2012-03-27 2013-10-03 Massachusetts Institute Of Technology Artificial sigma factors based on bisected t7 rna polymerase
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
EP2912180A1 (en) 2012-10-29 2015-09-02 Technische Universität Dortmund T7 rna polymerase variants and methods of using the same
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
US20150315541A1 (en) 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
PL3019619T3 (en) 2013-07-11 2022-01-10 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015058069A1 (en) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
WO2015143318A1 (en) * 2014-03-20 2015-09-24 The Board Of Regents Of The University Of Texas System T7 rna polymerase variants with expanded substrate range and enhanced transcriptional yield
RU2746406C2 (en) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Vaccines based on nucleic acids
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
JP2017523777A (en) 2014-07-17 2017-08-24 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Polynucleotide end modification
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
US20190008887A1 (en) 2015-07-30 2019-01-10 ModernaTX Inc. Multimeric mrna
US20190008938A1 (en) 2015-07-30 2019-01-10 Modernatx, Inc. Concatemeric peptide epitope rnas
WO2017031241A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Rna mapping/fingerprinting
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
SI3350157T1 (en) 2015-09-17 2022-04-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
HUE055458T2 (en) 2015-09-21 2021-11-29 Trilink Biotechnologies Llc Compositions and methods for synthesizing 5'-capped rnas
ES2810701T5 (en) 2015-10-05 2024-07-11 Modernatx Inc Procedures for the therapeutic administration of messenger ribonucleic acid drugs
CA3001852A1 (en) 2015-10-14 2017-04-20 Translate Bio, Inc. Modification of rna-related enzymes for enhanced production
WO2017066789A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. Human cytomegalovirus vaccine
EP3365007A4 (en) 2015-10-22 2019-07-03 ModernaTX, Inc. Broad spectrum influenza virus vaccine
BR112018008090A2 (en) 2015-10-22 2018-11-13 Modernatx Inc herpes simplex virus vaccine.
WO2017070618A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
PE20181529A1 (en) 2015-10-22 2018-09-26 Modernatx Inc NUCLEIC ACID VACCINES FOR VARICELA-ZOSTER VIRUS (VZV)
MA46317A (en) 2015-10-22 2019-08-07 Modernatx Inc RESPIRATORY SYNCYTIAL VIRUS VACCINE
WO2017070616A2 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
PT3718565T (en) 2015-10-22 2022-07-20 Modernatx Inc Respiratory virus vaccines
DK3386484T3 (en) 2015-12-10 2022-07-04 Modernatx Inc COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
AU2016369612B2 (en) 2015-12-17 2023-06-01 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
JP7114465B2 (en) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of drugs
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
CN116144626A (en) * 2016-01-13 2023-05-23 新英格兰生物实验室公司 Thermostable variants of T7RNA polymerase
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
MA45032A (en) 2016-05-18 2019-03-27 Fundacion Para La Investig Medica Aplicada POLYNUCLEOTIDES CODING FOR PORPHOBILINOGEN DESAMINASE FOR THE TREATMENT OF ACUTE INTERMITTEN PORPHYRIA
EP3458108A4 (en) 2016-05-18 2020-04-22 ModernaTX, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
MA45036A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING CITRINE FOR THE TREATMENT OF CITRULLINEMIA TYPE 2
EP3458106A4 (en) 2016-05-18 2020-03-18 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
AU2017266932B2 (en) 2016-05-18 2023-04-20 Modernatx, Inc. Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
LT3458083T (en) 2016-05-18 2023-02-10 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
MA45051A (en) 2016-05-18 2019-03-27 Modernatx Inc RELAXIN-CODING POLYNUCLEOTIDES
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
EP3458105B1 (en) 2016-05-18 2024-01-17 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
WO2018075980A1 (en) 2016-10-21 2018-04-26 Modernatx, Inc. Human cytomegalovirus vaccine
MA46643A (en) 2016-10-26 2019-09-04 Modernatx Inc METHODS AND COMPOSITIONS FOR RNA MAPPING
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
US10907165B2 (en) 2016-10-31 2021-02-02 Cornell University Methods of enhancing translation ability and stability of RNA molecules, treatments, and kits
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
AU2018214556A1 (en) 2017-02-01 2019-08-15 Modernatx, Inc. Immunomodulatory therapeutic mRNA compositions encoding activating oncogene mutation peptides
MA47438A (en) 2017-02-01 2019-12-11 Modernatx Inc SECONDARY POLYNUCLEOTIDE STRUCTURE
EP3576751A4 (en) 2017-02-01 2021-08-04 ModernaTX, Inc. Rna cancer vaccines
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. High potency immunogenic compositions
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
JP7332478B2 (en) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド Lipid nanoparticle formulation
EP4186888A1 (en) 2017-03-15 2023-05-31 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
MA49463A (en) 2017-04-26 2021-05-05 Modernatx Inc HERPES SIMPLEX VACCINE
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
US10034951B1 (en) * 2017-06-21 2018-07-31 New England Biolabs, Inc. Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
CA3066767A1 (en) 2017-06-30 2019-01-03 Codexis, Inc. T7 rna polymerase variants
JP2020530266A (en) 2017-06-30 2020-10-22 コデクシス， インコーポレイテッド T7 RNA polymerase variant
WO2019036670A2 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Efficacious mrna vaccines
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. Analytical hplc methods
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
EA202090919A1 (en) 2017-10-31 2020-09-09 Модернатикс, Инк. Lipid Nanoparticles for the Delivery of Modified RNA Encoding VEGF-A POLYPEPTIDE
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
AU2018372922A1 (en) 2017-11-21 2020-06-11 Modernatx, Inc. Epstein-Barr virus vaccines
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
SG11202012770RA (en) 2018-06-27 2021-01-28 Modernatx Inc Personalized cancer vaccine epitope selection
EP3863645A4 (en) 2018-09-13 2022-11-16 ModernaTX, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
CA3113353A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US20220047518A1 (en) 2018-09-19 2022-02-17 Moderna TX, Inc. Peg lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US20220125899A1 (en) 2018-11-07 2022-04-28 Modernatx, Inc. Rna cancer vaccines
CA3128215A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3927821A4 (en) 2019-02-20 2023-01-25 ModernaTX, Inc. Rna polymerase variants for co-transcriptional capping
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. Fed-batch in vitro transcription process
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
MA56060A (en) 2019-05-31 2022-04-06 Modernatx Inc EXPANDED T LYMPHOCYTE ASSAY
US20220348900A1 (en) 2019-08-14 2022-11-03 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription
US20220347292A1 (en) 2019-09-11 2022-11-03 Modernatx, Inc. Human cytomegalovirus vaccine
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
AU2020348860A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Cap guides and methods of use thereof for RNA mapping
US20210217484A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Variational autoencoder for biological sequence generation
US20210228707A1 (en) 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
BR112022015053A2 (en) 2020-01-30 2022-09-20 Modernatx Inc IMMUNIZING COMPOSITIONS AGAINST RESPIRATORY VIRUS
IL294866A (en) 2020-01-31 2022-09-01 Modernatx Inc Methods of preparing lipid nanoparticles
AU2021215938A1 (en) 2020-02-07 2022-09-01 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
US20230181481A1 (en) 2020-05-15 2023-06-15 Modernatx, Inc. Rna formulations for high volume distribution, and methods of using the same for treating covid-19
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
EP4153238A1 (en) 2020-05-21 2023-03-29 ModernaTX, Inc. Methylene blue stabilized mrna compositions
JP2023528484A (en) 2020-06-05 2023-07-04 モデルナティエックス インコーポレイテッド Bacterial strains for DNA production
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022067010A1 (en) 2020-09-25 2022-03-31 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
EP4277653A1 (en) 2021-01-15 2023-11-22 ModernaTX, Inc. Variant strain-based coronavirus vaccines
US20240100151A1 (en) 2021-01-15 2024-03-28 Moderna TX, Inc. Variant strain-based coronavirus vaccines
IL305644A (en) 2021-03-05 2023-11-01 Modernatx Inc Vlp enteroviral vaccines
JP2024511179A (en) 2021-03-26 2024-03-12 モデルナティエックス インコーポレイテッド pertussis vaccine
TW202304944A (en) 2021-03-31 2023-02-01 美商現代公司 Synthesis of trinucleotide and tetranucleotide caps for mrna production
US20240229109A1 (en) 2021-04-01 2024-07-11 Modernatx, Inc. Methods for identification and ratio determination of rna species in multivalent rna compositions
US20240209068A1 (en) 2021-04-01 2024-06-27 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
AU2022258335A1 (en) 2021-04-13 2023-11-23 Modernatx, Inc. Respiratory virus combination vaccines
WO2022221336A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
CA3216490A1 (en) 2021-04-13 2022-10-20 Modernatx, Inc. Epstein-barr virus mrna vaccines
EP4322994A1 (en) 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use

Also Published As

Publication number Publication date
US10526629B2 (en) 2020-01-07
JP2023129421A (en) 2023-09-14
JP2020532963A (en) 2020-11-19
EP3668971A4 (en) 2021-05-05
US20200131550A1 (en) 2020-04-30
US20210395792A1 (en) 2021-12-23
EP4397757A2 (en) 2024-07-10
US20190309337A1 (en) 2019-10-10
US11066686B2 (en) 2021-07-20
US11767548B2 (en) 2023-09-26
EP3668971B1 (en) 2024-04-10
JP7408098B2 (en) 2024-01-05
US20240102066A1 (en) 2024-03-28
EP3668971B8 (en) 2024-05-29
EP3668971A1 (en) 2020-06-24
CN111212905A (en) 2020-05-29
WO2019036682A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
MA49913A (en) RNA POLYMERASE VARIANTS
MA49421A (en) RNA FORMULATIONS
MA44479A (en) TRANSREPLICANT RNA
MA47680A (en) THERAPEUTIC RNA
MA46643A (en) METHODS AND COMPOSITIONS FOR RNA MAPPING
EP3464313A4 (en) 5'-cyclo-phosphonate modified nucleotides
FR3036037B1 (en) PERFECTIONAL ENHANCEMENT HARNESS
MA46717A (en) HOMING TCRA ENDONUCLEASIS VARIANTS
IL271547A (en) T7 rna polymerase variants
IL271553A (en) T7 rna polymerase variants
IL277921A (en) Novel small activating rna
DK3714101T3 (en) Lane change
ITUA20163609A1 (en) "MICRO-COGENERATOR".
FR3036295B1 (en) WINE AERATION ACCESSORY
UA32582S (en) BOOKLET "NOTE-MEP"
IT201700090331A1 (en) "LOPEMIDE"
IT201700071679A1 (en) REMEMBEBE '
ITUA20163709A1 (en) "PRESENTOSA3D"
UA35840S (en) "KAGOR" WINE LABEL
UA33845S (en) LABEL FOR "NASHA DOLYA" VODKA
UA33844S (en) LABEL FOR "POLISKA" VODKA
UA32473S (en) "GLASS" EMBLEM
UA32240S (en) "TIRAMISBAR" SIGN
UA32431S (en) STREMYANKA
UA32051S (en) "LETTER" EMBLEM